Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.
Joy
Melanie S
MS
School of Medicine, University of North Carolina at Chapel Hill, UNC Kidney Center and Division of Nephrology and Hypertension, CB 7155, 7005 Burnett Womack Building, Chapel Hill, NC 27599-7155, USA. melanie_joy@med.unc.edu
Frye
Reginald F
RF
Stubbert
Kristi
K
Brouwer
Kim R
KR
Falk
Ronald J
RJ
Kharasch
Evan D
ED
D000328:Adult; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000378:metabolism*; D018687:Antidepressive Agents, Second-Generation / Q000493:pharmacokinetics*; D001189:Aryl Hydrocarbon Hydroxylases / Q000378:metabolism*; D016642:Bupropion / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D002908:Chronic Disease; D065702:Cytochrome P-450 CYP2B6; D005260:Female; D006801:Humans; D008181:Lupus Nephritis / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010089:Oxidoreductases, N-Demethylating / Q000378:metabolism*; D010641:Phenotype; D013237:Stereoisomerism
D018687:Antidepressive Agents, Second-Generation; D016642:Bupropion; D001189:Aryl Hydrocarbon Hydroxylases; C585599:CYP2B6 protein, human; D065702:Cytochrome P-450 CYP2B6; D010089:Oxidoreductases, N-Demethylating; C496215:radafaxine